Mantle Cell Lymphoma
Expert Perspective
The Evolving Treatment Paradigm for Diffuse Large B-Cell Lymphoma
News
FDA approves pirtobrutinib for previously treated CLL/SLL
FDA greenlights pirtobrutinib as third-line treatment for chronic lymphocytic leukemia or small lymphocytic lymphoma in adults.
Expert Perspective
CAR T-Cell Therapy: Promising Treatments in Development for DLBCL
Expert Perspective
What’s New in Diffuse Large B-cell Lymphoma?
News
Lymphoma specialist to lead MD Anderson’s cancer medicine division
Dr. Christopher Flowers, a prominent African American oncologist with expertise in blood cancer and health disparity research, heads a key...
Expert Perspective
Emerging Treatment Options for Mantle Cell Lymphoma
Roundtable Discussion
Mantle Cell Lymphoma Roundtable Discussion
Expert Perspective
The Evolving Role for Transplantation in Mantle Cell Lymphoma
News
FDA approves pirtobrutinib for r/r mantle cell lymphoma
Pirtobrutinib for relapsed or refractory mantle cell lymphoma has been approved by the Food and Drug Administration.
News
MCL: Event-free survival at 2 years bodes well
With current therapies, patients who achieve 24 months of event-free survival live almost as long as the general population.
Conference Coverage
MCL: Ibrutinib could become the ‘new standard’
New research showed ibrutinib outperformed HSCT for treating younger patients with mantle cell lymphoma.